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Abstract
Background: Coffee oil potently raises serum cholesterol levels in humans. The diterpenes
cafestol and kahweol are responsible for this elevation. Coffee oil also causes elevation of liver
enzyme levels in serum. It has been suggested that cafestol is mainly responsible for the effect on
serum cholesterol levels and that kahweol is mainly responsible for the effect on liver enzyme
levels. The objective of this study was to investigate whether coffee oil that only contains a minute
amount of kahweol indeed does not cause elevation of liver enzyme levels.
Methods:  The response of serum alanine aminotransferase (ALAT) and aspartate
aminotransferase (ASAT) to Robusta coffee oil (62 mg/day cafestol, 1.6 mg/day kahweol) was
measured in 18 healthy volunteers.
Results: After nine days one subject was taken off Robusta oil treatment due to an ALAT level of
3.6 times the upper limit of normal (ULN). Another two subjects stopped treatment due to other
reasons. After 16 days another two subjects were taken off Robusta oil treatment. One of those
subjects had levels of 5.8 ULN for ALAT and 2.0 ULN for ASAT; the other subject had an ALAT
level of 12.4 ULN and an ASAT level of 4.7 ULN. It was then decided to terminate the study. The
median response of subjects to Robusta oil after 16 days was 0.27 ULN (n = 15, 25th,75th percentile:
0.09;0.53) for ALAT and 0.06 ULN (25th,75th percentile -0.06;0.22) for ASAT.
Conclusions: We conclude that the effect on liver enzyme levels of coffee oil containing hardly
any kahweol is similar to that of coffee oil containing high amounts of kahweol. Therefore it is
unlikely that kahweol is the component of coffee oil that is responsible for the effect. Furthermore,
we conclude that otherwise unexplained elevation of liver enzyme levels observed in patients might
be caused by a switch from consumption of filtered coffee to unfiltered coffee.
Background
Consumption of unfiltered coffee types raises serum cho-
lesterol levels in humans [1-4]. Unfiltered coffee also
causes elevated liver enzyme levels in serum. Cafestol and
kahweol are responsible for the effect of unfiltered coffee
on serum cholesterol. These diterpenes are present in the
oil derived from coffee beans. The only difference
between cafestol and kahweol is a double bond present
between the C1–C2 atoms in kahweol.
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Two types of coffee beans are used for brewing coffee: Ara-
bica and Robusta. Arabica beans contain both cafestol and
kahweol, whereas Robusta beans contain half as much
cafestol and hardly any kahweol [5]. Cafestol raises serum
cholesterol more potently than kahweol does. A mixture
of cafestol (60 mg/day) and kahweol (51 mg/day)
increased serum cholesterol only slightly more than pure
cafestol (64 mg/day) did [3]. Results with pure kahweol
are not available due to difficulties with purification and
stability of this diterpene.
Coffee oil also raises serum levels of the liver enzyme
alanine aminotransferase (ALAT) and to a lesser extent
aspartate aminotransferase (ASAT). Elevation of these
liver enzymes may indicate injury of hepatocytes [6-8].
For example in acute hepatitis, either viral or drug-
induced, both ALAT and ASAT are elevated. The ALAT lev-
els often exceed the ASAT levels. ALAT is predominantly
present in the cytosol of hepatocytes and ASAT is predom-
inantly present in the mitochondria. When hepatocytes
sustain damage to their membranes ALAT is released from
the cytosol, whereas when hepatocytes sustain more
severe damage ASAT is released from the mitochondria [6-
8]. When ASAT levels are more increased than ALAT levels;
this could indicate obstruction of the bile duct or alcohol
abuse.
We have earlier suggested that kahweol is mainly respon-
sible for the effect of coffee oil on liver enzyme levels
[3,9]. A mixture of cafestol and kahweol raised liver
enzyme levels more potently than pure cafestol, whereas
the effect on serum cholesterol levels is similar. This
would suggest that the structural difference between cafes-
tol and kahweol causes these diterpenes to act on different
pathways in the liver. On the basis of the suggestion that
kahweol is mainly responsible for the effect on liver
enzyme levels, we hypothesized that Robusta oil, which
contains a negligible amount of kahweol, would induce
no or a smaller response of liver enzymes than Arbica oil,
while maintaining its cholesterol-raising effect. In order to
test this hypothesis we designed a study in which healthy
volunteers consumed Robusta oil.
Methods
Subjects
Subjects were recruited among the student population of
Wageningen, a university town in the Netherlands.
Twenty-one volunteers were included; their health was
assessed by means of a questionnaire, and blood and
urine testing. We used the following eligibility criteria:
serum cholesterol < 8 mmol/l, serum triglycerides < 3.0
mmol/l, no glucosuria, normal liver enzyme activities in
serum, normal bilirubin levels in serum, no use of medi-
cation with effects on serum lipids, no consumption of
unfiltered coffee, and no history of gastrointestinal or
liver disease. The following enzyme activities were meas-
ured in serum: ALAT, ASAT, alkaline phosphatase, amy-
lase, γ-glutamyltranspeptidase and lactate dehydrogenase.
Three subjects were excluded at baseline due to serum
bilirubin concentrations above the upper limit of normal.
Thus, eighteen subjects were enrolled in the study. The
Medical Ethics Committee of Wageningen University and
Research Centre approved the study. It was determined a
priori that subjects would be taken off treatment as soon
as ALAT levels exceeded 2.5 times upper limit of normal
or ASAT levels exceeded 1.5 times the upper limit of nor-
mal. Each volunteer gave an informed consent.
Study design
Green robusta coffee beans were roasted and ground.
Robusta oil was extracted by hexane extraction under
food-grade conditions at the Agrotechnology & Food
Innovations institute in Wageningen. To make ingestion
more convenient the oil was administered as an emulsion
containing 50% Robusta oil with 50% water. Subjects
consumed 2 ml of Robusta oil twice a day for four weeks
resulting in a daily dose of 62 mg cafestol and 1.6 mg kah-
weol (samples analyzed using DIN 10779, 1999).
After two days of Robusta oil consumption the first blood
sample was taken for determination of liver enzyme activ-
ities. From then on blood was drawn every seven days and
liver enzyme activities were determined in the serum
within 24 hours. ALAT (Alanine Aminotransferase Flex
reagent cartridge, Dade Behring) and ASAT (Aspartate
Aminotransferase Flex reagent cartridge, Dade Behring)
were measured at 37°C. Liver enzyme activities are given
in multiples of the upper limit of normal because activi-
ties vary with the temperature used when determining
liver enzyme activities in different laboratories. The upper
limits of normal at this laboratory were 45 IU/l for ALAT
and 50 IU/l for ASAT.
Subjects were asked to maintain their lifestyles and dietary
habits for the duration of the study. They reported the
amount of coffee oil taken daily and changes in diet,
smoking, physical activity, use of medication, and illness,
in diaries.
Statistical analysis
To calculate the effect of Robusta oil on liver enzyme lev-
els we subtracted baseline levels from levels after treat-
ment for each subject. We tested the differences between
baseline and treatment levels with the Wilcoxon signed-
rank test. We present median differences with the 25th and
75th percentile. The responses of serum cholesterol and
triglycerides were also calculated as the level after treat-
ment minus the baseline level for each subject. Serum
lipid responses are presented as means with 95% confi-
dence intervals (CI95%)Nutrition Journal 2004, 3:7 http://www.nutritionj.com/content/3/1/7
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We used Bayesian statistics to combine existing evidence
of the effect of coffee oil on levels of serum cholesterol
with the present data. The Bayes factor was derived from
the P value of the Student's t test: Bayes factor = exp(-Z2/
2), where Z is the Z score that corresponds to the P value
obtained with the Student's t test. A priori probabilities
were converted to a priori odds and multiplied by the
Minimum Bayes factor to obtain a posteriori odds. Finally
the a posteriori odds were converted to a posteriori prob-
abilities [10].
P values reflect the probability of obtaining the observed
results or more extreme ones under the null hypothesis. A
priori probabilities reflect our a priori estimation of the
probability of the null hypothesis on the basis of the cur-
rent literature. A posteriori probabilities reflect the proba-
bility of the null hypothesis when combining a priori
evidence with evidence from the current study. We
assigned an a priori probability of 10% to the null
hypothesis that the effect of Robusta oil on serum choles-
terol levels was equal to zero. The rationale for this postu-
lation is that the effect of coffee oil on serum cholesterol
is well established [1-4].
Results
Eighteen subjects were enrolled in the study, three men
and 15 women. Figure 1 shows the number of subjects
that were screened, enrolled, and excluded. Table 1 pro-
vides baseline characteristics of the enrolled subjects. Dur-
ing the study two subjects withdrew: one because of an
infectious disease and the other because of the taste of the
coffee oil. After nine days one subject was taken off treat-
ment due to an ALAT level of 3.6 times the upper limit of
normal (ULN). After 16 days another two subjects had to
stop due to elevated ALAT and ASAT levels. One of those
subjects had a level of 5.8 ULN for ALAT and 2.0 ULN for
ASAT; the other subject had an ALAT level of 12.4 ULN
and an ASAT level of 4.7 ULN. It was then decided to ter-
minate the study, as prescribed by the study protocol:
Three subjects or more showing a liver enzyme level above
2.5 times upper limit of normal for ALAT or 1.5 times the
upper limit of normal for ASAT.
Diagram of the number of subjects that were screened, enrolled, and excluded Figure 1
Diagram of the number of subjects that were screened, enrolled, and excluded. ULN = times the upper limit of normal.Nutrition Journal 2004, 3:7 http://www.nutritionj.com/content/3/1/7
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Response of liver function parameters to Robusta oil
The median response after 16 days of coffee oil consump-
tion was an increase of 0.27 ULN (25th,75th  percen-
tile:0.09,0.53) for ALAT and 0.06 ULN (25th,75th
percentile: -0.06,0.22) for ASAT.
Table 2 shows levels of liver function parameters for all
subjects that received Robusta oil treatment for 16 days.
Follow-up measurements took place at termination, and
after four and eight weeks. After four weeks two subjects
had ALAT levels above normal. One of those subjects
showed a large response of ALAT after 16 days of treat-
ment, the other subject did not show a response above the
upper limit of normal during the treatment period. After
eight weeks ALAT and ASAT levels of all subjects were
within normal limits again. We observed no significant
effect of Robusta oil on alkaline phosphatase, amylase,
bilirubin, γ-glutamyltranspeptidase and lactate dehydro-
genase levels after 16 days of Robusta oil consumption.
However, during the follow-up measurement four weeks
after termination we observed increased levels of serum
bilirubin and decreased levels of alkaline phophatase.
Compared to baseline values bilirubin was increased by
3.0  µmol/l (25th,75th  percentile: -2.5,6) and alkaline
phosphatase was decreased by 0.05 ULN (25th,75th per-
centile:-0.16,-0.01).
Serum lipid response to Robusta oil
Total serum cholesterol levels were raised 0.27 mmol/l (n
= 15, CI95% -0.11;0.64) after 16 days of coffee oil treat-
ment. According to the Student's t test this effect was not
significantly different from 0 at the p < 0.05 level. How-
ever, Bayesian analysis showed that the evidence from this
study actually reduces an a priori probability for no effect
on cholesterol of 10% to an a posteriori probability of
4%. See table 3 for the Bayesian analysis including the
posteriori probabilities at several a priori probabilities.
Serum triglycerides were elevated by 0.46 mmol/l (CI95%
0.26;0.66) in the 15 subjects who were in the study after
16 days.
Discussion
Robusta oil caused a rise of ALAT levels of more than 2.5
times the upper limit of normal in three out of eighteen
subjects (17%). In our previous study with Arabica oil we
observed ALAT levels of more than 2.5 times the upper
limit of normal in eight out of 50 subjects (16%) in the
first period and in five of 40 subjects (13%) not in the
first, but only in a second treatment period [11]. Therefore
we conclude that the effect of Robusta oil on liver enzyme
levels is similar to that of Arabica oil. Levels of ASAT were
less affected by coffee oil than ALAT levels. ALAT is pre-
dominantly present in the cytosol of hepatocytes, whereas
ASAT is predominantly present in the mitochondria. This
could mean that the outer membranes of hepatocytes
have become leaky but that the cells are still largely intact.
When hepatocytes sustain more severe damage, the serum
levels of ASAT would exceed those of ALAT [6-8]. ALAT
levels were also elevated in subjects after daily consump-
tion of unfiltered coffee for six months [12], but were not
elevated in life-long consumers [1,13]. This suggests that
the effect of unfiltered coffee on ALAT levels is transient
when consumed over long periods of time and that possi-
bly an adaptation mechanism is present.
Another marker of liver damage, γ-glutamyltranspepti-
dase (γGT), has been shown to decrease during consump-
tion of boiled coffee. After withdrawal of treatment with
coffee lipids or coffee oil an rebound increase above base-
line values in serum levels of γGT is observed [1,3,14,15].
In the present study we observed a 14% decrease in serum
activities of γGT during treatment and an increase of 17%
compared to baseline eight weeks after termination. These
effects are not statistically significant in the present study.
This is due to the limited number of subjects and the short
duration of the coffee oil treatment. We also observed a
Table 1: Baseline characteristics for all subjects who started the study
Characteristic (n = 18)
Age (years) 22 ± 5
Height (m) 1.73 ± 0.09
Weight (kg) 64.3 ± 10.3
Body mass index (kg/m2) 21.3 ± 1.6
Serum total cholesterol (mmol/l) 4.4 ± 1.0
Serum triglycerides (mmol/l) 0.85 ± 0.38
Alanine aminotransferase (IU/l) 20 ± 8
Aspartate aminotransferase (IU/l) 16 ± 4
Current smokers n (%) 2 (11)
Alcohol (glass/week) median (25th percentile, 75th percentile) 8 (2, 15)
Variables presented as mean ± sd, current smokers presented as n (%), and alcohol consumption as median with the 25th and 75th percentile.Nutrition Journal 2004, 3:7 http://www.nutritionj.com/content/3/1/7
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7% decrease in serum activities of alkaline phosphatase
compared to baseline four weeks after termination. A ten-
dency of alkaline phosphatase to be decreased during cof-
fee lipid treatment was observed in previous studies [1,3].
Bilirubin levels were 38% increased during the follow-up
measurement after four weeks compared to baseline. We
observed no effect of Robusta oil treatment on amylase, a
marker for pancreatitis, or lactate dehydrogenase, which is
used for diagnosis of heart, muscle, and liver diseases.
Increases of γGT and bilirubin after stopping treatment
with coffee oil could indicate cholestasis. Cholestasis is
functionally defined as a disruption in secretion of bile
acids from the liver. Disrupted secretion causes elevated
levels of bile acids in the liver, which causes damage to the
hepatocytes. However, in cholestatic disease alkaline
phosphatase is strongly increased, which is not the case
with coffee oil treatment.
In Scandinavia, where large amounts of unfiltered coffee
were commonly consumed, risk of coronary heart disease
is high and was associated with consumption of unfiltered
coffee but mortality rates of liver cirrhosis have been typi-
cally low [16]. Therefore, it is unlikely that consumption
of unfiltered coffee produces severe damage to the liver.
However, it is possible that unfiltered coffee can cause
sub-clinical hepatic injury in some individuals. At present
we have no evidence that the changes in liver enzyme lev-
els induced by coffee oil or unfiltered coffee are of clinical
relevance. Because we have no liver biopsies from subjects
we are not able to demonstrate possible liver damage in
vivo. No results from animal studies showing the effect of
coffee oil on the liver have been published.
Interestingly, cafestol and kahweol have been shown to
upregulate detoxification pathways in the liver of rat and
mice and human cultured cells [17-21]. This effect on
detoxification is hypothesized to explain the observed
inverse association between coffee consumption and cer-
tain cancer types [20,22-24]. Possibly, cafestol upregulates
these pathways due to its toxicity and as a "side effect"
enhances detoxification of carcinogenic compounds.
Table 2: levels of liver parameters at baseline after Robusta oil treatment and during follow-up
Parameter Normal limits Baseline Treatment Follow-up1 Follow-up 2
n = 15 n = 15 n = 14 n = 14
Alanine aminotransferase < 45 IU/l 0.38 [0.36,0.56] 0.67 [0.58,1.27]** 0.49 [0.39,0.72]* 0.39 [0.35,0.53]
Aspartate aminotransferase < 50 IU/l 0.32 [0.26,0.38] 0.44 [0.26,0.56] 0.32 [0.28,0.42] 0.38 [0.28,0.41]
Alkaline phosphatase 40 – 125 U/l 0.45 [0.36,0.58] 0.43 [0.35,0.54] 0.42 [0.34,0.51]* 0.49 [0.37,0.53]
Amylase 35 – 130 U/l 0.50 [0.45,0.61] 0.48 [0.38,0.52] 0.49 [0.46,0.58] 0.47 [0.42,0.57]
Bilirubin < 17 umol/l 0.47 [0.41,0.65] 0.53 [0.35,0.65] 0.65 [0.57,0.82]** 0.53 [0.40,0.74]
γ-glutamyltranspeptidase < 40 U/l for women
< 75 U/l for men
0.29 [0.24,0.38] 0.25 [0.20,0.45] 0.31 [0.27,0.51] 0.34 [0.25,0.46]
Lactate dehydrogenase 230 – 485 IU/l 0.60 [0.56,0.61] 0.61 [0.49,0.65] 0.60 [0.50,0.64] 0.54 [0.52,0.65]
All values are medians in units of times the upper limit of normal with the 25th and 75th percentile between brackets. Treatment values were 
obtained after 16 days of Robusta oil treatment. Follow-up 1 took place four weeks after termination of the intervention and Follow-up2 eight 
weeks after termination. * value differs significantly from baseline (p < 0.05) in the Wilcoxon signed-rank test. ** p < 0.01
Table 3: Change in prior probabilities of cafestol not affecting serum cholesterol to posterior probabilities using data of the present 
study and Bayesian analysis
Prior probability Prior odds (Yes/No) Posterior odds Posterior probability
0.90 (very strong) 0.9/(1-0.9) = 9 9x Bayes factor = 3.22 3.22/(1+3.22) = 0.76
0.75 (strong) 0.75/(1-0.75) = 3 3x Bayes factor = 1.07 1.07/(1+1.07) = 0.52
0.50 (equivocal) 0.50/(1-0.50)= 1 1x Bayes factor = 0.36 0.36/(1+1.07) = 0.26
0.25 (weak) 0.25/(1-0.25) = 0.33 0.33x Bayes factor = 0.12 0.12/(1+0.12) = 0.11
0.10 (very weak) 0.10/(1-0.10) = 0.11 0.11x Bayes factor = 0.04 0.04(1+0.04) = 0.04
A priori probabilities were converted to a priori odds and multiplied by the minimum Bayes factor*. The obtained a postiori odds were converted 
to a postiori probabilities. *Bayes factor = e to the power -Z2/2, where Z is the Z-score corresponding to the P-value for obtaining an effect of 0.27 
mmol/l under the null hypothesis. P-value = 0.15, Z-score = 1.43 the minimum Bayes factor = 0.36Nutrition Journal 2004, 3:7 http://www.nutritionj.com/content/3/1/7
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After 16 days of Robusta oil treatment serum cholesterol
levels were elevated but this effect was not statistically sig-
nificant at the P < 0.05 level according to the conventional
frequentist analysis. This was expected from previous
studies: the full effect on serum cholesterol is only
observed after 4–6 weeks of coffee oil consumption. After
four weeks daily consumption of 62 mg of cafestol results
in a rise in serum cholesterol of 0.8 mmol/l. The Bayesian
analysis, however, indicates that the present study in fact
reinforces the existing evidence that coffee oil raises serum
cholesterol, independent of how strong one judges this
prior evidence to be (Table 3). We also found that triglyc-
erides were elevated after 16 days of treatment, which was
also expected from previous studies [1-4].
On the basis of our results it is not likely that it is kahweol,
which is mainly responsible for the effect of coffee oil on
liver enzyme levels, as has been suggested in two previous
studies [3,9]. In most subjects coffee oil caused elevation
of liver enzyme levels. However, this elevation was more
extreme in a small number of subjects. Figure 2 shows
ALAT levels and figure 3 shows ASAT levels of subjects at
baseline and after 16 days of coffee oil consumption.
Although no parallel placebo group was present in this
study it is unlikely that such large responses of liver
enzymes would be observed with placebo oil. This is
supported by previous studies with coffee and placebo oil
[1,9,25]. We found no correlation between the response
of liver enzymes to coffee oil and baseline liver enzyme
activities, serum lipid response, or alcohol. Moreover, a
previous study showed that the liver enzyme response is
not consistent within subjects [11]. In this study we also
found no correlation between alcohol intake and liver
enzyme response. Although we cannot rule out the possi-
bility that alcohol affected the liver enzyme response dur-
ing the study it does not seem likely that alcohol intake
could fully explain the observed increases in ALAT and
ASAT. Furthermore, γGT is decreased rather than increased
during consumption of coffee oil, whereas alcohol causes
increases in γGT levels.
Together with the observation that most subjects do not
show such a large increase in liver enzyme levels during
coffee oil treatment, this suggests that an unknown envi-
ronmental factor enhances the response of liver enzymes
to coffee oil in a number of subjects. We conclude that
increased ALAT or ASAT activities in patients may be
caused by a switch from filtered to unfiltered coffee. If
ALAT levels of subjects at baseline and after 16 days of Robusta oil consumption Figure 2
ALAT levels of subjects at baseline and after 16 days of Robusta oil consumption. The horizontal line indicates the upper limit 
of normal.Nutrition Journal 2004, 3:7 http://www.nutritionj.com/content/3/1/7
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raised activities of ALAT and ASAT are caused by a change
in coffee consumption, the ratio ASAT/ALAT will be
smaller then 1 and other markers of liver damage such as
γGT and alkaline phophatase will be typically within nor-
mal limits. When otherwise unexplained elevation of
ALAT and ASAT activities are observed it would be
advisable to ask a patient if he/she consumes large
amounts of unfiltered coffee such as French press coffee.
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